Moleculin Biotech Inc
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas. Show More...
-
Website https://www.moleculin.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 0.87 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD -0.4 -0.53 -0.46 -0.32 -0.2 Dividends USD Payout Ratio % * Shares Mil 10.0 19.0 26.0 41.0 46.0 Book Value Per Share * USD 0.87 0.52 0.41 0.25 Free Cash Flow Per Share * USD -0.38 -0.48 -0.44 Return on Assets % -47.82 -54.66 -60.8 -58.92 -44.36 Financial Leverage (Average) 1.1 1.14 1.37 1.62 1.67 Return on Equity % -55.24 -61.13 -75.67 -88.5 -69.21 Return on Invested Capital % -51.91 -61.13 -75.67 -86.3 -67.93 Interest Coverage -89.86 Current Ratio 3.88 3.75 2.06 3.78 4.26 Quick Ratio 3.72 3.48 1.84 3.01 3.6 Debt/Equity 0.02 0.02